Opioid Rotation and Conversion Calculator

How to Use This Calculator

1. Select current opioid and enter daily dose.
2. Select target opioid and choose cross-tolerance reduction percentage.
3. Calculated equianalgesic and recommended starting dose appear instantly.
4. Full Rotation tab: compare 100%, 75%, and 50% reduction doses side-by-side.
5. Professional tier: renal impairment adjustments and monitoring plan.

Formula

Example

Frequently Asked Questions

• What is opioid rotation and why is it performed? ▼
  Opioid rotation (also called opioid switching or substitution) is the practice of switching a patient from one opioid analgesic to another to improve the balance between analgesia and adverse effects. The clinical indications for opioid rotation are: inadequate analgesia despite dose escalation (opioid-resistant pain or tolerance), intolerable side effects at effective analgesic doses (nausea, constipation, pruritus, sedation, cognitive impairment, myoclonus), opioid-induced hyperalgesia (paradoxical increase in pain sensitivity with increasing doses), development of renal or hepatic impairment altering opioid metabolism, change in clinical status requiring a different route of administration (e.g., IV to oral, oral to subcutaneous infusion), and formulary or insurance restrictions. Opioid rotation exploits the phenomenon of incomplete cross-tolerance: prolonged exposure to one opioid develops tolerance at mu-receptors that is not fully shared with other opioids due to receptor-level differences in binding, downstream signaling pathways, and allosteric receptor conformations. This means that when rotating from one opioid to another, patients are relatively less tolerant to the new opioid and require a dose reduction of 25–50% from the strict equianalgesic equivalent to avoid over-dosing.
• What is incomplete cross-tolerance and how much dose reduction is needed? ▼
  Incomplete cross-tolerance is the observation that tolerance developed to one opioid does not fully transfer to another opioid of the same class. This occurs because different opioids have different binding profiles at mu-receptor subtypes, activate different intracellular signaling cascades (G-protein versus beta-arrestin pathways), and occupy receptors in slightly different conformational states. The clinical consequence is that when calculating an equianalgesic dose during rotation, applying a straight equianalgesic conversion without reduction will typically result in over-dosing because the patient is less tolerant to the new opioid than expected from the equianalgesic table. Standard clinical practice recommends reducing the calculated equianalgesic dose by 25–50% when initiating the new opioid. The 25% reduction is appropriate for most opioid rotations in patients who have no signs of opioid toxicity and are in mild-to-moderate pain. A 50% reduction is recommended for frail, elderly, or medically complex patients and when rotating to a more potent opioid such as hydromorphone or fentanyl. When rotating because of intolerable side effects (suggesting relative over-treatment rather than under-treatment), a more conservative 50% reduction is often used. Conversely, when rotating because of inadequate analgesia, some clinicians use a 25% reduction rather than 50%. Individualized titration in the 24–48 hours after rotation is essential regardless of which approach is used.
• Which opioids are safest in renal impairment? ▼
  Renal function profoundly affects opioid pharmacokinetics because many opioids are metabolized to active or toxic compounds that require renal excretion. Morphine is metabolized in the liver to morphine-6-glucuronide (M6G, which has analgesic activity) and morphine-3-glucuronide (M3G, which is neuroexcitatory and can cause myoclonus, cognitive impairment, and seizures). Both metabolites accumulate significantly in renal failure, making morphine poorly safe in CKD stage 4–5 and ESRD. If morphine must be used, doses should be reduced by 25–50% and interval extended. Hydromorphone is metabolized to hydromorphone-3-glucuronide (H3G), which is neuroexcitatory; accumulation is less problematic than morphine metabolites in mild-moderate CKD but remains a concern in severe CKD. Fentanyl is considered the opioid of choice in renal failure because it is metabolized to inactive compounds (norfentanyl) that do not accumulate clinically in moderate CKD, though some caution is warranted in ESRD. Oxycodone metabolites (oxymorphone, noroxycodone) can accumulate in severe renal impairment. Codeine is contraindicated in renal failure due to accumulation of morphine metabolites from codeine conversion. Tramadol's active metabolite (O-desmethyltramadol) and its seizure risk are amplified in renal impairment — reduce dose and extend interval in CKD. The UK palliative care reference Palliative Care Formulary (PCF) provides detailed opioid dosing recommendations in renal impairment.
• How are breakthrough (PRN) opioid doses calculated? ▼
  Breakthrough pain dosing, also called rescue dosing or PRN dosing, follows a validated formula based on the total daily opioid dose (expressed as MEDD). The standard guideline-recommended PRN dose is 10–15% of the total 24-hour MEDD, available every 4 hours as needed. This percentage was derived empirically from clinical observation and pharmacokinetic modelling. For example, a patient on an MEDD of 90 mg/day would be prescribed a breakthrough dose of 9–13.5 mg oral morphine every 4 hours as needed. When the PRN route differs from the baseline opioid route (e.g., IV rescue for a patient on oral maintenance), the dose must be recalculated using route-specific equianalgesic ratios. For hydromorphone IV rescue: MEDD × 0.125 / 20 (hydromorphone IV factor). If a patient is using more than 3 breakthrough doses per day consistently, this is a signal that the baseline opioid dose is inadequate and should be increased — typically by adding 50–100% of the total daily PRN dose used in the previous 24 hours to the scheduled dose. High PRN usage is an important clinical trigger for reassessing pain management and should be documented during palliative care rounds and pain service consultations.
• What are the risks of getting opioid conversion wrong? ▼
  Medication errors in opioid conversion are among the most consequential errors in clinical pharmacology and are responsible for a significant proportion of preventable opioid-related deaths in hospital settings. A 2011 analysis by the Institute for Safe Medication Practices (ISMP) identified opioid conversions as one of the highest-risk medication processes. Common error types include: applying conversion ratios in the wrong direction (e.g., treating fentanyl patch mcg/hr as if equivalent to mg/day), failing to apply cross-tolerance reduction, confusing IR (immediate release) and ER (extended release) formulations during conversion, not accounting for route changes (oral vs. IV vs. transdermal), applying methadone equianalgesic ratios incorrectly (methadone is uniquely non-linear), and calculation arithmetic errors particularly in pediatric dosing. A 10-fold dosing error with fentanyl — for example, administering 100 mcg instead of 10 mcg IV — can be rapidly fatal due to respiratory arrest. Safe practices include: independent double-check by pharmacist, automatic clinical decision support alerts for high-MEDD prescriptions, use of standardized conversion tables rather than mental arithmetic, clear documentation of all opioid prescriptions in a single medication reconciliation view, bedside monitoring after rotation (hourly vital signs including oxygen saturation for 4 hours), and routine pharmacist review of all new opioid orders.

Related Calculators